Insider Selling: LifeStance Health Group (NASDAQ:LFST) Director Sells $45,094.00 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 6,442 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.00, for a total transaction of $45,094.00. Following the completion of the sale, the director owned 1,378,954 shares of the company’s stock, valued at approximately $9,652,678. This represents a 0.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Robert Bessler also recently made the following trade(s):

• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total transaction of $86,597.00.
• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total transaction of $558,206.30.

LifeStance Health Group Stock Performance

Shares of NASDAQ:LFST opened at $7.05 on Monday. The firm has a 50 day moving average of $5.99 and a 200 day moving average of $5.37. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of -235.00 and a beta of 1.13. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. The business had revenue of $363.81 million for the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The business’s revenue was up 16.3% compared to the same quarter last year. During the same period last year, the business posted ($0.02) EPS. On average, sell-side analysts predict that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LFST has been the topic of a number of analyst reports. BTIG Research lifted their price objective on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. BMO Capital Markets initiated coverage on shares of LifeStance Health Group in a report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price target on the stock. Barclays assumed coverage on LifeStance Health Group in a report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective for the company. UBS Group raised their price objective on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Wall Street Zen lowered LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

Institutional Investors Weigh In On LifeStance Health Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. purchased a new stake in LifeStance Health Group in the first quarter valued at approximately $7,932,000. Squarepoint Ops LLC lifted its stake in LifeStance Health Group by 259.1% during the 2nd quarter. Squarepoint Ops LLC now owns 1,360,054 shares of the company’s stock valued at $7,031,000 after acquiring an additional 981,349 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in shares of LifeStance Health Group by 43.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 230,000 shares of the company’s stock valued at $1,532,000 after acquiring an additional 70,000 shares during the last quarter. TD Asset Management Inc acquired a new stake in shares of LifeStance Health Group in the second quarter worth $780,000. Finally, AXQ Capital LP purchased a new position in shares of LifeStance Health Group during the second quarter worth $343,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.